Novo Nordisk adapts Rybelsus launch to the coronavirus era
Novo Nordisk integrated COVID-19 education into its launch strategy for diabetes treatment Rybelsus.
Coronavirus
Five things for pharma marketers to know: Thursday, July 9, 2020
Coronavirus cases in U.S. pass 3 million; Walgreens partners with VillageMD; Biogen submits Alzheimer’s drug for FDA approval.
Coronavirus Briefing: Schools plan for the fall, beachgoer shaming, and a patient-confidence rebound
This week’s Haymarket Media Coronavirus Briefing is 1,261 words and will take you seven minutes to read.
AbelsonTaylor/Veeva report: Physicians are adjusting to COVID-era uncertainty, but want support from pharma
For “Managing Uncertainty: Helping Physicians Survive in the Short-Term and Thrive in the Long-Term,” the companies surveyed 550 doctors.
Five things for pharma marketers to know: Wednesday, July 8, 2020
Novavax receives $1.6b for COVID-19 vaccine; Trump begins process of withdrawal from WHO; PPE shortages return as cases spike.
Five things for pharma marketers to know: Tuesday, July 7, 2020
Doctors urge WHO to acknowledge airborne transmission of COVID-19; FDA approves Becton Dickinson’s rapid antigen test; Webcast: Leverage machine learning, AI to improve trial recruitment.
Excerpt: Health media in the COVID-19 era
Dr. Judith Simmons talks social media follows, voices from the frontlines and coverage blind spots.
Arthur Sadoun warns of ‘very tough days’ ahead as Publicis fights to return to growth
He delivered last Sunday message to Publicis staff.
Coronavirus Briefing: Reopening goes awry, Remdesivir’s price tag and the point-of-care pivot
This week’s Haymarket Media Coronavirus Briefing is 1,388 words and will take you seven minutes to read.
Gilead names remdesivir price
The treatment will cost $3,120 for a five-day treatment course for a patient with private insurance in the U.S.
